

Xinnate Appoints Erik Kinnman as Chairman of the Board

Seasoned biotech leader to support next growth phase and phase 2/3 development

Lund, Sweden –June 12, 2026

Xinnate AB, a Swedish clinical-stage biotechnology company developing novel peptide-based therapies, today announced that Erik Kinnman has been elected Chairman of the Board at the Annual General Meeting.

Erik Kinnman succeeds Lena Mårtensson, who has led the company through its transition from an early-stage venture to a clinical-stage biotech with its lead candidate, TCP-25, in Phase 2/3 development.

The leadership transition comes at an important stage as Xinnate advances its global Phase 2/3 STEP study evaluating the company’s proprietary TCP-25 gel in patients with Epidermolysis Bullosa (EB), a rare and severe genetic skin disease, while preparing for potential partnering and commercialization opportunities.

“I am excited about and honoured to join Xinnate as Chairman at such an important stage in the company’s development,” says Erik Kinnman. “The TCP-25 program addresses a significant unmet medical need, and I am impressed by the strong scientific foundation and progress achieved to date. I look forward to working with the Board and management to define and execute on the next strategic steps, including advancing clinical development and exploring partnership opportunities to bring this promising therapy to patients.”

“Xinnate has made remarkable progress during my tenure, evolving from an early-stage venture into a company with a robust clinical program and a clear vision for the future,” says Lena Mårtensson. “With the ongoing STEP study and important milestones ahead, now is the right time to transition leadership. I am confident that Erik’s experience and strategic insight will be invaluable as Xinnate enters its next phase.”

“I want to thank Lena Mårtensson for her contribution, and I am very pleased to welcome Erik Kinnman as Chairman of the Board,” says Helene Hartman, CEO of Xinnate. “Erik brings a unique combination of scientific, clinical, and strategic expertise that will be instrumental as we build on the strong foundation established under Lena’s leadership.

His extensive experience in the life sciences sector makes him the ideal person to guide Xinnate through the next stage of growth.”

Erik Kinnman, MD, PhD, is an Associate Professor at Karolinska Institutet with more than 30 years of experience in the life sciences industry. He has held senior roles at AstraZeneca and Sobi, as well as served as CEO of Sprint Bioscience and Abliva. He is currently CEO of Vivesto AB, and Chairman of Edvance AB.

About Xinnate AB

Xinnate is a Swedish clinical-stage drug development company developing novel therapies based on its unique, groundbreaking peptide technology. These therapies address dysfunctional healing by modulating the interaction between microbes and inflammatory processes. With an ambitious development program, Xinnate is dedicated to improving the lives of, primarily, patients with Epidermolysis Bullosa. Xinnate is a member of the SmiLe Venture Hub at Medicon Village in Lund.

About TCP-25

TCP-25 is a novel immunomodulatory peptide with demonstrated anti-inflammatory, antimicrobial, and wound-healing properties. Xinnate’s lead drug candidate, TCP-25 gel, is a topical formulation developed for the treatment of Epidermolysis Bullosa (EB).

About the STEP study

The STEP study, protocol number TCP25-002, is a double-blinded, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed dystrophic EB (DEB) or junctional EB (JEB). The study uses intra-individual randomization, meaning that a pair of matched index wounds are randomized to local treatment with either TCP-25 gel or placebo. Approximately 32 patients from 4 years of age will be included in the study. The study is conducted in France, Greece, Italy, Spain, Sweden, and the United States.

For more information about the study, please see www.clinicaltrials.gov, ID: NCT06594393.